Literature DB >> 1882209

Update on the clinical efficacy and side effects of clozapine.

A Safferman1, J A Lieberman, J M Kane, S Szymanski, B Kinon.   

Abstract

Clozapine (CLOZ) is an atypical antipsychotic drug being used with increasing frequency throughout the world and has recently been commercially marketed in the United States. Its unique properties make it a promising but challenging drug to use in the treatment of schizophrenia. In order to use CLOZ most effectively and efficiently, clinicians must be aware of its potential benefits and risks. This report is a review and critical evaluation of current knowledge regarding the clinical efficacy and side effects of CLOZ. Although CLOZ has proven to be effective in some treatment-refractory schizophrenic patients and to produce relatively few extrapyramidal side effects compared to classical neuroleptic drugs, several issues require further investigation including what defines neuroleptic intolerance, the optimal dose range, and the appropriate duration of a CLOZ treatment trial. Similarly, studies are needed to determine what role CLOZ should have in the treatment of patients with predominantly negative symptoms and those patients who are only partially responsive to standard neuroleptics. In addition, important questions remain as to what other conditions might be indications for CLOZ, for example, schizoaffective disorder, affective psychoses, and idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882209     DOI: 10.1093/schbul/17.2.247

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  47 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

2.  Managing pathologic aggression in people with psychotic disorders.

Authors:  Dominique Bourget; Alain Labelle
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

3.  Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.

Authors:  Anil Purohit; Carol Smith; Katharine Herrick-Davis; Milt Teitler
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

4.  Quetiapine (Seroquel) shows a pattern of behavioral effects similar to the atypical antipsychotics clozapine and olanzapine: studies with tremulous jaw movements in rats.

Authors:  A Betz; K Ishiwari; A Wisniecki; N Huyn; J D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

5.  Aripiprazole-induced seizure: a second case report.

Authors:  Che-Lin Yueh; Sung-Lin Yu; Hsiao-Min Chen; Bo-Jian Wu; Wen-Ching Chen
Journal:  BMJ Case Rep       Date:  2009-07-14

Review 6.  Clozapine-induced sialorrhea: pathophysiology and management strategies.

Authors:  Samir Kumar Praharaj; Manu Arora; Sachin Gandotra
Journal:  Psychopharmacology (Berl)       Date:  2006-03-03       Impact factor: 4.530

7.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 8.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake.

Authors:  Susana Mingote; Mariana Pereira; Andrew M Farrar; Peter J McLaughlin; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-01-17       Impact factor: 3.533

10.  Use of aripiprazole in clozapine induced enuresis: report of two cases.

Authors:  Myung-Ji Lee; Chul-Eung Kim
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.